|
Video: What is a Stock Split?
|
|
Adverum Biotechnologies is a clinical-stage company focused on establishing gene therapy as a standard of care for ocular diseases. Co.'s main product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection. According to our ADVM split history records, Adverum Biotechnologies has had 1 split. | |
|
Adverum Biotechnologies (ADVM) has 1 split in our ADVM split history database. The split for ADVM took place on March 21, 2024. This was a 1 for 10 reverse split, meaning for each 10 shares of ADVM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Adverum Biotechnologies conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ADVM split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adverum Biotechnologies shares, starting with a $10,000 purchase of ADVM, presented on a split-history-adjusted basis factoring in the complete ADVM split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/07/2014 |
|
End date: |
10/03/2024 |
|
Start price/share: |
$315.40 |
|
End price/share: |
$7.28 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.69% |
|
Average Annual Total Return: |
-31.41% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$230.70 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
03/21/2024 | 1 for 10 |
|
|